Clinical approach to diffuse large B cell lymphoma

Blood Rev. 2016 Nov;30(6):477-491. doi: 10.1016/j.blre.2016.06.003. Epub 2016 Jun 30.

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of lymphoma. We now recognize that DLBCL corresponds to a biologically heterogeneous family of diseases. Given the potential for cure for most DLBCL patients, appropriate diagnostic and staging evaluation and therapy are essential. Here we review areas of consensus as well as controversy in the evaluation, treatment and monitoring of patients with DLBCL and its related subtypes.

Keywords: Autologous stem cell transplant; Chemotherapy; Diffuse large B cell lymphoma (DLBCL); Novel targeted therapy for lymphoma.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Decision-Making
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Disease Management
  • Drug Resistance, Neoplasm
  • Humans
  • Immunotherapy
  • Lymphoma, Large B-Cell, Diffuse / diagnosis*
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Neoplasm Staging
  • Recurrence
  • Treatment Outcome